Synbio International Inc. has been approved for Deposit/Withdrawal at Custodian and Direct Registration System processing through its transfer agent, Pacific Stock Transfer Company. This development represents an important step in the company’s ongoing efforts to modernize its trading infrastructure and improve accessibility for both existing shareholders and prospective investors.
DWAC eligibility enables electronic transfer of shares between broker-dealers and the company’s transfer agent, eliminating the need for physical share certificates, reducing settlement times, and lowering transaction friction for more efficient trading in the open market. In parallel, DRS allows shareholders to hold their shares directly on the books of the company in electronic form, without requiring a physical certificate or intermediary custody. This provides investors with greater control, enhanced ownership security, and simplified transferability.
‘Achieving DWAC and DRS eligibility is a foundational step in strengthening Synbio’s capital markets platform,’ said Claudio Solitario, CEO of Synbio International. ‘As we continue to advance our strategic initiatives, including our planned financing activities and partnership developments, it is critical that our stock is easily accessible and efficiently tradable for the investment community.’
This development comes as Synbio continues to transition toward a more investor-ready, execution-focused public company platform, with multiple near-term capital markets and operational catalysts expected. The company, which focuses on clinically validated AI-driven medical diagnostics, aims to bridge the gap between wellness and medicine through strategic partnerships and research collaborations. More information about the company’s initiatives can be found at https://www.synbiointl.com.
The modernization of trading infrastructure through DWAC and DRS processing positions the company to move quickly as it executes on a number of near-term initiatives currently in progress. This technical advancement in trading capabilities is particularly significant for a medical research and technology company seeking to develop science-based solutions that improve quality of life and empower healthcare providers.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Synbio International Achieves DWAC and DRS Eligibility to Modernize Trading Infrastructure.